| AF | Atrial Fibrillation |
| ANP/NT-proANP | Atrial natriuretic peptide/N-terminal-proANP |
| ASCVD | Atherosclerotic cardiovascular disease |
| BNP/NT-proBNP | Brain/B-type natriuretic peptide/N-terminal-proBNP |
| CKD | Chronic kidney disease |
| CSS | Clinical summary score |
| CV | Cardiovascular |
| EF | Ejection fraction |
| eGFR | Estimated glomerular filtration rate |
| ESRD | End-stage renal disease |
| HF | Heart failure |
| HFrEF | Heart failure with reduced ejection fraction |
| HFpEF | Heart failure with preserved ejection fraction |
| HHF | Hospitalization due to heart failure |
| HR | Hazard ratio |
| KCCQ | Kansas City Cardiomyopathy Questionnaire |
| LVEF | Left ventricular ejection fraction |
| MACE | Major adverse cardiac events |
| NO | Nitric oxide |
| NPs | Natriuretic peptides |
| NYHA | New York Heart Association |
| OMT | Optimal medical therapy |
| RAAS | Renin-angiotensin-aldosterone system |
| SGLT-2i | Sodium-glucose cotransporter-2 inhibitors |
| SNS | Sympathetic nervous system |
| T2DM/T1DM | Type 2/Type 1 diabetes mellitus |